Cargando…
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520404/ https://www.ncbi.nlm.nih.gov/pubmed/28649983 http://dx.doi.org/10.1038/bcj.2017.57 |
| _version_ | 1783251813862998016 |
|---|---|
| author | Witzig, T E LaPlant, B Habermann, T M McPhail, E Inwards, D J Micallef, I N Colgan, J P Nowakowski, G S Ansell, S M Johnston, P B |
| author_facet | Witzig, T E LaPlant, B Habermann, T M McPhail, E Inwards, D J Micallef, I N Colgan, J P Nowakowski, G S Ansell, S M Johnston, P B |
| author_sort | Witzig, T E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5520404 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55204042017-07-26 High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) Witzig, T E LaPlant, B Habermann, T M McPhail, E Inwards, D J Micallef, I N Colgan, J P Nowakowski, G S Ansell, S M Johnston, P B Blood Cancer J Letter to the Editor Nature Publishing Group 2017-06 2017-06-23 /pmc/articles/PMC5520404/ /pubmed/28649983 http://dx.doi.org/10.1038/bcj.2017.57 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spellingShingle | Letter to the Editor Witzig, T E LaPlant, B Habermann, T M McPhail, E Inwards, D J Micallef, I N Colgan, J P Nowakowski, G S Ansell, S M Johnston, P B High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title_full | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title_fullStr | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title_full_unstemmed | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title_short | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) |
| title_sort | high rate of event-free survival at 24 months with everolimus/rchop for untreated diffuse large b-cell lymphoma: updated results from ncctg n1085 (alliance) |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520404/ https://www.ncbi.nlm.nih.gov/pubmed/28649983 http://dx.doi.org/10.1038/bcj.2017.57 |
| work_keys_str_mv | AT witzigte highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT laplantb highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT habermanntm highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT mcphaile highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT inwardsdj highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT micallefin highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT colganjp highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT nowakowskigs highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT ansellsm highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance AT johnstonpb highrateofeventfreesurvivalat24monthswitheverolimusrchopforuntreateddiffuselargebcelllymphomaupdatedresultsfromncctgn1085alliance |